Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070096 · ClinicalTrials.gov registry record · Phase 2
Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00070096: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00070096 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00070096, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well ixabepilone works in treating patients with metastatic germ cell tumors that are refractory to cisplatin.
Interventions
- DRUG ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2003-08 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070096
The ClinicalTrials.gov registry entry for NCT00070096 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ixabepilone is the first listed.
NCT00070096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00070096 about?
NCT00070096 is a clinical study titled "Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors". RATIONALE: Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well ixabepilone works in treating patients with metastatic germ cell tumors that are refractory to cisplati...
What is the current status of trial NCT00070096?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2003-08. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00070096?
The interventions under investigation include: ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00070096?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.